Skip to main content

Table 2 Characteristics of studies included in this meta-analysis

From: The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis

First author (Year)

Country

Ethnicity

Genotyping methods

Matching criteria

Sample size (case/control)

Source of control

BC ascertainment

Quality scores

HWE(P value)

Yao 2013

China

Asian

TaqMan Assay

Age

162/190

HB

PC

7

0.540

Menzel Tyrol 2004

Austria

Caucasian

5′ exonuclease assay

Region

218/424

PB

HC

7.5

0.175

Menzel Prague 2004

Czech

Caucasian

5′ exonuclease assay

Age, region

190/231

PB

HC

7

0.650

Siegelmann-Danieli 2002

America

Caucasian

PCR-SSCP

Age, region

346/235

PB

HC

6

0.869

Singh 2010

India

Asian

PCR-RFLP

Age, smoking, region

200/200

HB

Other

5.5

0.000

Hamajima 2002

Japan

Asian

PCR-CTPP

NA

237/640

HB

HC

6

0.046

Sarmanova 2004

Czech

Caucasian

PCR-RFLP

Age, ethnicity

238/310

HB

HC

6

0.576

Aston 2005

America

Caucasian

PCR-RFLP

Age, region

564/1212

PB

Other

8.5

0.549

Hong 2007

America

Caucasian

TaqMan Assay

Age, ethnicity

496/495

PB

Other

7

0.531

Lajin 2013

Syria

Arab

ARMS-PCR

Ethnicity

122/139

PB

HC

7.5

0.253

  1. BC, Breast cancer; HC, Histologically confirmed; PC, Pathologically confirmed; NA, Not available; PB, Population–based; HB, Hospital–based; HWE, Hardy–Weinberg equilibrium in control population; PCR–RFLP, Polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP, Polymerase chain reaction-single strand conformation polymorphism; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; ARMS-PCR, amplification refractory mutation system-PCR.